Scout Bio Expands Gene Therapy Collaboration with the University of Pennsylvania Via Next-Generation Vector Technologies Partnership agreement includes exclusive rights in animal health to novel viral vector capsid and expands additional option rights to novel capsidsNext-generation novel adeno-associated viral (AAV)...

Scout Bio Named Best New Start-Up for 2021 PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Scout Bio, a biotechnology company focused on one-time AAV gene therapies for major chronic pet health conditions, received top honors as the Best...

Scout Bio Initiates Multi-Center Clinical Study of Gene Therapy for Chronic Arthritis Pain In Cats - First vectorized antibody gene therapy to be studied in pets- Strong initial in-species data support therapeutic profile of one-time gene therapy designed for long-term pain management- Novel...

Scout Bio Closes $33 Million Series B2 Financing to Advance its Portfolio of Single Injection Gene Therapy Technology for the Treatment of Chronic Diseases in Pets - Proceeds to support advancing single injection Adeno-Associated Viral (AAV) vector therapeutics targeting chronic companion animal diseases including diabetes, pain, and anemia associated with...

Scout Bio Successfully Completes Pilot Clinical Study of SB-001, a Single-Injection AAV Gene Therapy for the Treatment of Feline CKD-Associated Anemia PHILADELPHIA, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Scout Bio today announced the successful completion of a CKD-associated anemia study in client owned cats treated with SB-001, an AAV expressing...